Yunnan Botanee Bio-Technology Group Co.LTD

SZSE:300957 Stock Report

Market Cap: CN¥19.5b

Yunnan Botanee Bio-Technology GroupLTD Past Earnings Performance

Past criteria checks 1/6

Yunnan Botanee Bio-Technology GroupLTD has been growing earnings at an average annual rate of 9.4%, while the Personal Products industry saw earnings growing at 6.4% annually. Revenues have been growing at an average rate of 20.9% per year. Yunnan Botanee Bio-Technology GroupLTD's return on equity is 9.9%, and it has net margins of 9.7%.

Key information

9.4%

Earnings growth rate

6.5%

EPS growth rate

Personal Products Industry Growth7.8%
Revenue growth rate20.9%
Return on equity9.9%
Net Margin9.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Earnings Troubles May Signal Larger Issues for Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Shareholders

Nov 02
Earnings Troubles May Signal Larger Issues for Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Shareholders

Yunnan Botanee Bio-Technology GroupLTD's (SZSE:300957) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 02
Yunnan Botanee Bio-Technology GroupLTD's (SZSE:300957) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Recent updates

Earnings Troubles May Signal Larger Issues for Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Shareholders

Nov 02
Earnings Troubles May Signal Larger Issues for Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Shareholders

Is Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Trading At A 39% Discount?

Oct 19
Is Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Trading At A 39% Discount?

The Market Lifts Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Shares 26% But It Can Do More

Sep 27
The Market Lifts Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Shares 26% But It Can Do More

Is Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) A Risky Investment?

Sep 25
Is Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) A Risky Investment?

Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Will Pay A Smaller Dividend Than Last Year

Jun 03
Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Will Pay A Smaller Dividend Than Last Year

A Look At The Fair Value Of Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957)

May 24
A Look At The Fair Value Of Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957)

Yunnan Botanee Bio-Technology GroupLTD's (SZSE:300957) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 02
Yunnan Botanee Bio-Technology GroupLTD's (SZSE:300957) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Has A Pretty Healthy Balance Sheet

Feb 29
Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Has A Pretty Healthy Balance Sheet

Revenue & Expenses Breakdown

How Yunnan Botanee Bio-Technology GroupLTD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300957 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246,1085923,535317
30 Jun 245,9597913,235304
31 Mar 245,7567753,145298
31 Dec 235,5227573,036299
30 Sep 235,5501,1132,712310
30 Jun 235,3321,1062,590282
31 Mar 235,0691,0642,424258
01 Jan 235,0141,0512,390255
30 Sep 224,8051,0252,353171
30 Jun 224,6609932,270152
31 Mar 224,3239302,107121
01 Jan 224,0228631,932113
30 Sep 213,3326831,62285
30 Jun 213,1076481,45082
31 Mar 212,8255681,37872
31 Dec 202,6365441,28163
31 Dec 191,94441298451
31 Dec 181,24026163243
31 Dec 1779815441528

Quality Earnings: 300957 has a large one-off gain of CN¥186.1M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300957's current net profit margins (9.7%) are lower than last year (20.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300957's earnings have grown by 9.4% per year over the past 5 years.

Accelerating Growth: 300957's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300957 had negative earnings growth (-46.8%) over the past year, making it difficult to compare to the Personal Products industry average (-10.1%).


Return on Equity

High ROE: 300957's Return on Equity (9.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 18:30
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yunnan Botanee Bio-Technology Group Co.LTD is covered by 42 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jian Jun ZouChasing Securities
Xiyue ZhangChasing Securities
Zhuonan XuChina International Capital Corporation Limited